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Abstract
Background: Autophagy has emerged as a key mechanism in the survival and function of T and B lymphocytes,
and its activation was involved in apoptosis resistance in rheumatoid arthritis (RA). To investigate whether the
relationship between autophagy and apoptosis may impact the response to the therapy, we analyzed ex vivo
spontaneous autophagy and apoptosis in patients with RA subjected to treatment with anti-tumor necrosis factor
(TNF) drugs and in vitro the effects of TNFα and anti-TNF drugs on cell fate.
Methods: Peripheral blood mononuclear cells (PBMCs) from 25 RA patients treated with anti-TNF drugs were
analyzed for levels of autophagy marker LC3-II by western blot and for the percentage of annexin V-positive
apoptotic cells by flow cytometry. The same techniques were used to assess autophagy and apoptosis after in vitro
treatment with TNFα and etanercept in both PBMCs and fibroblast-like synoviocytes (FLS) from patients with RA.
Results: PBMCs from patients with RA responsive to treatment showed a significant reduction in LC3-II levels,
associated with an increased apoptotic activation after 4 months of therapy with anti-TNF drugs. Additionally, the
expression of LC3-II correlated with DAS28. TNFα was able to induce autophagy in a dose-dependent manner after
24 h of culture in RA PBMCs and FLS. Moreover, etanercept caused a significant reduction of autophagy and of
levels of citrullinated proteins.
Conclusions: Our results show how the crosstalk between autophagy and apoptosis can sustain the survival of
immune cells, thus influencing RA progression. This suggests that inhibition of autophagy represents a possible
therapeutic target in RA.
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Background
Rheumatoid arthritis (RA) is a chronic autoimmune dis-
ease characterized by autoantibodies production as a re-
sult of breakage of immunological tolerance mechanisms
[1]. Different immune cell types including fibroblast-like
synoviocytes (FLS) and lymphocytes take part in both
joints-restricted and extra-articular manifestations of the
disease, and tumor necrosis factor alpha (TNFα) is
clearly the most important cytokine in RA [2, 3]. Despite
the relatively high efficacy of TNF antagonists, approxi-
mately one third of patients are intolerant or
non-responsive to such drugs, thus the discovery of new
therapeutic targets is desirable in RA management.
Autophagy (or macroautophagy) is an evolutionarily
conserved lysosomal degradation pathway in eukaryotic
organisms. During autophagy, portions of the cyto-
plasm are sequestered within characteristic double-
membrane vesicles known as autophagosomes and are
finally delivered to lysosomes for bulk degradation [4].
The products of autophagy-related gene (Atg) genes or-
chestrate every autophagy step ensuring the correct
advancing of the process. Moreover, the levels of
phosphatidylethanolamine-conjugated form of
microtubule-associated protein light chain 3 (LC3)-II
(LC3-II) are widely used to monitor autophagic activity
in cells [5, 6]. Recently, aberrant autophagy regulation
has been linked to a wide range of pathological condi-
tions, including autoimmune diseases. In T lymphocytes
from systemic lupus erythematosus (SLE) patients, an au-
tophagy-resistant behavior has been demonstrated, and a
critical role of this process is emerging in different aspects
of RA pathogenesis [7, 8].
Autophagy actively participates in protein citrullina-
tion and carbamylation by substrates for the formation
of autoantibodies [9, 10]. In fact, stimuli that induce au-
tophagy were able to activate PAD4 enzyme in FLS from
RA patients [9]. Also, ex vivo analysis in monocytes
from early-naïve RA patients revealed an interesting dir-
ect correlation between autophagy levels and anti-cyclic
citrullinated peptide (anti-CCP) titer. Recently, the same
experimental condition was used to demonstrate that
also carbamylation process was related to autophagy ac-
tivation [10].
Increased autophagy levels were detected in synovial
fibroblasts as well as in CD4+ T cells from RA patients,
and a possible protective role of autophagy against apop-
tosis was suggested [11, 12]. Up to now, few studies have
investigated the effect of TNF inhibitors on apoptosis
with controversial results and, despite the importance
of autophagy in immune-mediated mechanisms, how
these drugs influence autophagy has not been clarified
yet [13, 14].
In this study, to elucidate the possible role of autoph-
agy in response to anti-TNF therapy, we analyzed the
effect of anti-TNF drugs on the interplay between au-
tophagy and apoptosis both ex vivo and in vitro in per-
ipheral immune cells and synoviocytes from patients
with RA.
Methods
Patients
Twenty-five consecutive RA patients, fulfilling the 2010
ACR/EULAR criteria, were recruited from the Rheuma-
tology Unit of Sapienza University of Rome after signing
a written informed consent [15]. The study was ap-
proved by the Ethics Committee of Sapienza University
of Rome (protocol number 110/18). All patients were
naïve for anti-TNF drugs and were followed after 4
months of treatment with these drugs. At every visit,
clinical and laboratory assessments were performed and
EULAR response criteria were used to classify partici-
pants as responder or non-responders to the therapy.
For each patient, the following variables were recorded:
clinical data included the disease duration and activity of
RA, tender and swollen joint counts, and the patient’s
general assessment of his/her condition scored on a vis-
ual analog scale (VAS). The disease activity of RA was
determined in all patients with the Disease Activity
Score on 28 joints (DAS28) using C-reactive protein and
clinical disease activity index (CDAI).
PMBCs and FLS isolation
Peripheral blood mononuclear cells (PBMCs) were isolated
from RA patients by Ficoll–Hypaque density-gradient cen-
trifugation. Layer of mononuclear cells was collected and
then washed twice in phosphate-buffered saline (PBS) and
cultured in RPMI 1640 medium with 10% FBS supple-
mented with 2mM glutamine and 50mg/ml gentamycin.
Synovial tissue was collected from patients with RA
undergoing total knee replacement in London, after
obtaining their informed consent. Ethical approval was
granted by the East London and The City Research Ethics
Committee 3 (LREC07/Q0605/29). The patients’ mean
age was 73.25 years.
Fibroblast-like synoviocytes (FLS) were isolated imme-
diately after surgery by digestion of the synovial tissue
with Dispase at 37 °C for 60 min [16]. After washing, the
cells were grown in a Dulbecco’s modification of Eagle
medium (DMEM) supplemented with 10% FBS, 50 IU/ml
penicillin/streptomycin, 2mM glutamine, and 10mM
HEPES. For the experiments, synovial fibroblasts were
used between passages 4 and 8. Primary human fibroblast
cultures obtained from skin biopsy were used for prelim-
inary experiments.
Cell cultures
PBMCs and FLS were treated with recombinant human
TNFα (R&D) at concentrations of 5 and 10 ng/ml for 24
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h (time and concentrations were chosen after prelimin-
ary experiments) at 37 °C in a humidified incubator in
an atmosphere of 5% CO2.
To induce autophagy, starvation was performed by in-
cubating cells at lower concentration of fetal bovine
serum (1% FBS). Autophagic flux was assessed by adding
lysosomal protease inhibitors E64d and pepstatin A (Pep
A, both at 10 mg/ml; Sigma) for 2 h before the end of
the culture. For inhibition of autophagy, PBMCs were
treated with 10 mM 3-methyladenine (3-MA; Sigma).
Etanercept, purchased from the hospital pharmacy, was
diluted in cell medium at concentration of 15 μg/mL.
PBMCs and FLS were maintained in the incubator at 5%
CO2 and 37 °C and after 24 h of culture were collected
for analysis of autophagy, apoptosis, and citrullination.
Apoptosis detection
Apoptosis was measured using FITC-conjugated annexin
V (AV) and a propidium iodide (PI) apoptosis detection
kit (Marine Biological Laboratory) following manufac-
turer’s protocol. Fifty thousand events for each sample
were run on a FACSCalibur cytometer, and data were
analyzed using the CellQuest Pro software (BD). Re-
ported data refer to AV-positive apoptotic cells.
Cell sorting
For the separation of CD4+ T, CD8+ T, and B lymphocytes,
PBMCs from patients with RA were stained with surface
antigen-specific antibodies (Additional file 1: Figure S1) and
cell sorting was performed with the flow cytometer FACS
Aria (BD Biosciences). Purity of the enriched populations
was greater than 99% in all experiments.
Western blot
RA FLS and PBMCs were lysed in RIPA buffer in the pres-
ence of complete protease-inhibitor mixture (Roche). Ly-
sates (50 μg) were loaded on 15% (for autophagy analysis),
to 10% (for citrullinated proteins detection) and to 7.5%
(for PARP detection) SDS-polyacrylamide gel, and then
electrophoretically transferred onto PVDF membranes.
The membranes were incubated overnight at + 4 °C shak-
ing with rabbit anti-human LC3B antibody (Cell Signaling
Technology), rabbit anti-human PARP antibody (Cell
Signaling Technology), rabbit anti-human β-actin anti-
body (Sigma), and rabbit polyclonal anti-citrulline anti-
body (Millipore). The immunoreactivity was assessed by a
chemiluminescence reaction, and densitometry analysis
was used for the quantification of protein expression on
autoradiograms.
Anti-CCP antibodies assay
Quantification of serum levels of anti-CCP antibodies
was determined by commercial ELISA kit (Delta Biologi-
cals) in accordance with the manufacturer’s instructions.
A value of anti-CCP antibodies ≥ 30 U/mL was consid-
ered positive.
Statistical analysis
Data are expressed as mean ± standard deviation (SD) or
median (interquartile range). Differences between groups
were analyzed using the Mann-Whitney U test, and
Spearman test was used for correlation analysis. To
analyze the changes in autophagy and apoptosis levels
after therapy, the Wilcoxon signed rank test was used. P
values <0.05 were considered statistically significant.
Results
Clinical and serological characteristics of RA patients
Twenty-five patients with established RA naïve to bio-
logical agents (23 females and 2 males, mean age 59
years, mean duration of disease 6.3 years) were included
in this study. The baseline demographic, clinical, and la-
boratory parameters are shown in Table 1. In our cohort,
72% of patients with RA were positive for anti-CCP anti-
bodies and at time zero no clinical differences were ob-
served between anti-CCP positive and negative patients.
An additional number of eight patients with RA were
enrolled for sorting experiments (Additional file 1:
Table S1). After the failure of conventional synthetic
disease-modifying anti-rheumatic drug (csDMARDs),
all the patients started therapy with anti-TNF agents
[20 patients received etanercept (50 mg/week) and 5
adalimumab (40 mg/2 weeks)]. Thirteen patients were
in treatment with anti-TNF drugs plus methotrexate
(MTX, 10–20 mg weekly).
Spontaneous autophagy and apoptosis in RA patients
before and after treatment with anti-TNF drugs
To evaluate a possible relationship between autophagy
and RA progression, we analyzed the levels of spontan-
eous autophagy at baseline (t0) and after 4 months of
treatment (t4) with anti-TNF drugs in PBMCs isolated
from patients with RA. Patients were divided into two
groups according to the clinical response: we merged
good and moderate responders against non-responders.
As expected, the treatment significantly reduced DAS28
score in patients responding to treatment (from 4.3 ± 1.5
to 2.5 ± 1.1, P = 0.002). Conversely, no significant clinical
improvement was found in non-responders at 4 months
of follow-up.
We did not find differences in autophagy levels after
treatment with TNF inhibitors (data not shown); how-
ever, when patients with RA were divided based on re-
sponse to the therapy, we noticed that LC3-II levels
significantly decreased in PBMCs from responders (n = 17,
Fig. 1a). On the contrary, no significant change in autoph-
agy was found in patients non-responding to the therapy
(n = 8, Fig. 1a). In addition, a positive correlation between
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LC3-II levels and both DAS28 and CDAI was observed
(Fig. 1b).
Since MTX was found to induce autophagy in RAFLS
[17] and 13 patients of our cohort were taking anti-TNF
drugs in association with MTX, we evaluated the results
in light of this issue. As displayed in Additional file 1:
Figure S1, the reduction of autophagy and the increase
in apoptosis in responders was not influenced by con-
comitant MTX use.
The analysis of serum levels of anti-CCP antibodies in
responding patients revealed no statistically significant
reduction of anti-CCP titer after anti-TNF therapy. In
addition, no correlation with LC3-II levels and with the
percentage of AV-positive cells was found. In re-
sponders, autophagy and apoptosis were reduced both in
patients that were positive and negative for anti-CCP
antibodies (Additional file 1: Figure S2).
In order to clarify which lymphocyte subsets could be
involved in autophagy-dependent response to therapy,
we analyzed autophagy marker LC3-II in CD4+ and
CD8+ T and B lymphocytes from patients with RA
isolated by cell sorting technique (Additional file 1:
Figure S3). After 4 months of treatment with TNF antag-
onists, CD4+ T lymphocytes from responders showed a
statistically significant reduction of LC3-II levels
compared to the baseline (Fig. 1c). No significant change
in autophagy was found in CD8+ T cells and B cells
from both responders and non-responders to the ther-
apy (Fig. 1e, f ). Moreover, the analysis of the cleaved form
of PARP confirmed the increased levels of apoptosis after
therapy in CD4+ T cells from responders (Fig. 1d).
Considering the crucial role of autophagy in the regu-
lation of lymphocyte survival and the downregulation of
apoptosis observed in immune cells of patients with RA,
we focused on the variation in apoptosis in relation to
response to anti-TNF therapy [18, 19]. In patients
responding to anti-TNF therapy, the percentage of
AV-positive apoptotic cells increased after 4 months of
treatment (Fig. 2a), while the failure of the therapy was
associated with unchanged spontaneous apoptosis levels
(Fig. 2b). Moreover, a significant inverse correlation be-
tween LC3-II levels and the percentage of apoptotic cells
was observed in PBMCs from responders (Fig. 2c).
Effect of TNFα on autophagy in PBMCs from patients
with RA
Several studies have demonstrated that TNFα was able to
stimulate autophagy in different cell types, including
RAFLS [20–22]. Here, we confirmed the pro-autophagic
effect of this cytokine also in PBMCs from patients with
RA in a dose-dependent manner (Fig. 3a). On the con-
trary, incubation with TNFα did not significantly affect
apoptosis (Additional file 1: Figure S4). To assess whether
the accumulation of LC3-II after stimulation with TNFα
was due to upstream or downstream autophagy defect,
the autophagic flux was assayed in presence of the lyso-
somal proteases inhibitors E64d and Pep A, two blockers
of the degradation of the autophagolysosome content [6].
In the presence of these inhibitors, TNFα caused a further
increase in LC3-II levels, confirming the ability of TNFα
to induce autophagy in PBMCs from patients with RA
(Fig. 3b).
Considering the pro-autophagic effect of TNFα and
the enhanced apoptosis in patients responding to
anti-TNF therapy, we analyzed whether autophagy inhib-
ition in cells treated with TNFα affected apoptosis in
vitro. To this aim, PBMCs from patients with RA were
treated with TNFα in association with the autophagy in-
hibitor 3-MA for 24 h. As expected, LC3-II levels were
reduced after 3-MA treatment (Fig. 4a). Interestingly, the
co-treatment with TNFα and 3-MA caused a significant
increase in apoptosis (Fig. 4b), suggesting that autophagy
induced by TNFα was able to protect RA PBMCs from
apoptosis.
Effect of etanercept on autophagy, apoptosis, and
citrullination in PBMCs isolated from patients with RA
In order to possibly reproduce the in vivo conditions,
RA PBMCs were cultured in serum deprivation or in
Table 1 Baseline clinical and serological characteristics of
patients with RA
Characteristic Value
Demographic parameters
Sex, F/M 23/2
Age, mean (SD), years 59 (12.6)
Disease duration, mean (SD), years 6.3 (8.8)
Laboratory parameters
ESR, mean (mm/h) (SD) 17.6 (9.3)
CRP, mean (mg/dL) (SD) 0.68 (0.65)
RF positivity, n (%) 19 (76)
ACPA positivity, n (%) 18 (72)
Disease activity
TJ n, mean (SD) 5.8 (5.4)
SJ n, mean (SD) 2.6 (2.4)
CDAI, mean (SD) 19.3 (10.8)
DAS28, mean (SD) 4.2 (1.6)
Therapy
Etanercept, n (%) 20 (80)
Adalimumab, n (%) 5 (20)
Concurrent MTX, n (%) 13 (52)
SD standard deviation, ESR Erythrocyte Sedimentation Rate, CRP C-Reactive
Protein, RF Rheumatoid Factor, ACPA anti-citrullinated peptide antibodies, TJ
Tender joints, SJ swollen joints, CDAI Clinical Disease Activity Index, DAS28
Disease Activity Score on 28 joints, csDMARDs conventional synthetic disease-
modifying antirheumatic drugs
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presence of TNFα for 4 h, and then TNF-inhibitor was
added to the culture. After 24 h, autophagy, apoptosis,
and citrullination were evaluated. We used PBMCs from
RA patients naïve to anti-TNF therapy to avoid any in-
fluence of a previous exposition to anti-TNF on results.
The treatment with etanercept caused a statistically sig-
nificant reduction of LC3-II levels; moreover, inhibition
of autophagy by etanercept resulted more marked when
cells were exposed to TNFα and starvation (Fig. 5a). Eta-
nercept alone did not affect the percentage of AV-positive
cells, but interestingly a significant change in apoptosis
was obtained only when this compound was added after
pre-treatment with TNFα and in nutrient deprivation con-
dition (Fig. 5b).
Recently, different studies evaluated the role of au-
tophagy in the citrullination process, demonstrating that
autophagy is directly involved in the generation of
citrullinated proteins, both in synoviocytes and mono-
cytes [9]. Here, in order to confirm the inhibitory effect
of etanercept on autophagy, we analyzed levels of citrul-
linated proteins after in vitro treatment with TNFα and
etanercept in PBMCs isolated from RA patients. Lysates
from PBMCs analyzed by anti-citrulline antibody
showed the presence of numerous bands correspond-
ing to citrullinated proteins. Densitometric analysis
revealed a statistically significant reduction reduction
in the total amount of citrullinated proteins following
incubation with etanercept, confirming a direct rela-
tion between autophagy and citrullination (Fig. 5c).
Modulation of autophagy and apoptosis by etanercept in
FLSs from RA patients
Since RA most significant pathogenic events occur in
the synovium, we explored autophagic behaviour in
Fig. 1 Autophagy levels in PBMCs from RA responders and non-responders to anti-TNF drugs. a Western blot analysis of LC3-II in PBMCs
isolated from patients with RA before (t0) and after 4 months of treatment with anti-TNF drugs (t4). Samples from two responding and
two non-responding patients as representative of the total number of 25 analyzed are shown. Densitometry analysis of LC3-II levels
relative to β-actin is also displayed. ****P < 0.0001. b Correlation between autophagy and clinical parameters in PBMCs isolated from
patients with RA at baseline and after therapy with anti-TNF drugs. Spearman’s rank correlation coefficient and linear regression are
displayed. DAS 28, Disease Activity Score 28; CDAI, clinical disease activity index. c, d Autophagy and apoptosis levels in CD4+ T
lymphocytes from responders and non-responders. Western blot analyses of LC3-II (c) and of cleaved PARP (d) in CD4+ T lymphocytes
from patients with RA. Densitometry analyses are also shown. *P < 0.05. e, f Autophagy levels in CD8 + T and B lymphocytes from
responding and non-responding patients before and after treatment with anti-TNF drugs. Western blot analysis of autophagy marker
LC3-II in cell lysates obtained from CD8+ (e) and CD19+ (f) lymphocytes purified by cell sorting. Blots shown are representative of
independent experiments performed in T and B cells from eight patients with RA before and after treatment with anti-TNF drugs.
Densitometry analysis of LC3-II amount relative to β-actin is also shown
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response to in vitro treatment with etanercept also in
FLSs isolated from patients with RA. Following prelim-
inary experiments conducted on primary fibroblasts
(data not shown), the dosage of etanercept chosen for
the experiments was the same as the one used for
PBMCs. Autophagy and apoptosis were increased after
24 h of treatment with TNFα in RA FLS (Fig. 6a). The
adding of etanercept after treatment with TNFα and
starvation caused a significant reduction in LC3-II levels
as evidence of autophagy inhibition (Fig. 6a). In contrast
to the data obtained in peripheral cells, etanercept was
able to induce apoptosis in RA FLS. In addition, a fur-
ther increase in AV-positive cells was found when the
treatment with etanercept was performed in conditions
that activate autophagy like starvation and treatment
with TNFα (Fig. 6b).
Discussion
In this study, we clarified the role of autophagy in the
progression of RA by analyzing how the treatment with
anti-TNF drugs modulated autophagy both ex vivo and
in vitro. Although TNF inhibitors have revolutionized
the clinical approach of inflammatory immune-mediated
diseases, a substantial proportion of patients fails to re-
spond to anti-TNF therapy, reducing therapeutic options
and possibly leading to a rapid progression of the disease
[23, 24]. For this reason, the study of mechanisms influ-
encing the response to therapy has a crucial importance
in the identification of new therapeutic targets in RA.
Here, we analyzed the changes in spontaneous autoph-
agy in peripheral cells from patients with RA treated
with TNF inhibitors, demonstrating a reduction of au-
tophagy only in patients responding to the therapy. As
Fig. 2 Analysis of spontaneous apoptosis in PBMCs purified from patients with RA treated with anti-TNF drugs. a, b Percentage of
annexin V (AV)-positive cells by flow cytometry in PBMCs purified from patients with RA (n = 25) before (t0) and after 4 months (t4) of
treatment with anti-TNF drugs. Analysis of apoptosis was performed in responders (n = 17) (a) and non-responders (n = 8) (b), separately.
Representative dot plots (PI on y-axis vs. AV on x-axis) are also shown, ***P < 0.001. c Correlation and linear regression analysis of
autophagy and apoptosis expressed as LC3-II levels and percentage of AV-positive cells, respectively, in PBMCs from patients with RA
responding to anti-TNF therapy
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a result, the amount of LC3-II (at baseline and after
anti-TNF therapy) directly correlated with disease ac-
tivity score, showing that levels of autophagy may be
a measure of disease progression. Our results in per-
ipheral cells are in line with the data of Zhu and col-
leagues performed in the synovial tissue of active RA
patients [25]. Given that B and T lymphocytes need
autophagy for their maturation and activation [26], we
extended our analysis in lymphocyte subsets, reporting
a reduction of LC3-II levels and an increase in apop-
tosis also in CD4+ T lymphocytes from responding
patients. Although these results must be confirmed in
a large population, as already demonstrated in total
peripheral immune cells, also in CD4+ T lymphocytes
autophagy and apoptosis did not change in patients
who failed to respond to the treatment. These experi-
mental evidences suggest the possible use of
autophagy markers as expression of disease activity
and response to therapy in RA.
Autophagy is a physiological process that allows cells,
including lymphocytes, to survive during stress condi-
tions [27]. In this regard, recent papers deepened this as-
pect in the context of RA pathogenesis, suggesting a
direct involvement of autophagy in apoptosis resistance
in FLS and T cells [28]. Nonetheless, how the relation-
ship between these two processes impacts the response
to therapy has not been clarified yet. We demonstrated
that the percentage of apoptotic cells increased in
PBMCs from responding patients, and autophagy and
apoptosis were found to be inversely correlated in this
group of patients. Similar results were obtained by other
researchers at synovial level [29]. Our findings suggest
that autophagy participates in RA progression by pro-
moting the survival of inflammatory and autoreactive
Fig. 3 Effect of TNFα on autophagy in PBMCs from patients with RA. a Western blot analysis of LC3-II levels in PBMCs treated with TNFα at
concentration of 5 and 10 ng/mL for 24 h. As a control condition, cells were cultured in serum deprivation condition (1% FBS). Blots shown are
representative of five independent experiments performed in PBMCs from different patients with RA naïve to anti-TNF therapy. Densitometry
analysis of LC3-II levels relative to β-actin is also shown. **P < 0.01, *P < 0.05. b Western blot and densitometry analysis of LC3-II levels in lysates
from PBMCs treated with TNF-α and, when indicated, with E64d and PepA (added 2 h before the end of the culture). The figure was chosen as a
representative of those obtained from five independent experiments on cells from different RA patients never treated with anti-TNF
drugs. **P < 0.01
Vomero et al. Arthritis Research & Therapy           (2019) 21:39 Page 7 of 11
cells, thus impacting the response to therapy. In fact, we
hypothesize that PBMCs from patients with RA could
take advantage of autophagy to survive and to supply
energy for several pathological processes including mi-
gration to synovium.
By elimination of intracellular pathogens, delivered
and degraded into autophagosomes, autophagy has a
crucial role in the modulation of innate and adaptive
immunity response. For this reason, it is not surpris-
ing that cytokines involved in cellular defense, such
as TNFα, are also able to activate autophagy in differ-
ent cell types [30]. Referring to the last guidelines for
monitoring autophagy, we analyzed the autophagic
flux in RA PBMCs treated with TNFα using lyso-
somal proteases inhibitors [6]. Blocking the degrad-
ation of autophagolysosome content, these molecules
allow to understand if the increased levels of LC3-II
after incubation with TNFα were due to an effective
enhanced autophagy or rather to a defect on
autophagosome-lysosome fusion [7]. The use of lysosomal
proteases inhibitors increased autophagy levels in RA
PBMCs treated with TNFα compared with cells treated
with TNFα alone, confirming the ability of this cyto-
kine to induce autophagy. Moreover, we found that
treatment with TNFα in the presence of autophagy
inhibitor 3-MA made RA PBMCs more susceptible to
apoptosis induction. This result shows that autophagy
contributes to apoptosis resistance in these cells. In
addition, our results, according to previous published data
in a collagen-induced arthritis (CIA) mouse model, sug-
gest that the blockade of autophagy may be an interesting
clinical approach in RA [31].
Patients enrolled in this study were treated with
TNF inhibitors, drugs that suppress biological func-
tions of TNFα. It was indirectly noticed that the re-
activation of tuberculosis during anti-TNF therapy
may be associated with autophagy suppression [32],
but the effect of TNF inhibitors on autophagy has not
been investigated yet in vitro. We found that expos-
ition to etanercept, both alone and in conditions that
Fig. 4 Effect of autophagy inhibition in PBMCs from patients with RA treated with TNFα. a Western blot analysis of LC3-II in PBMCs treated with
the autophagy inhibitor 3-MA (10 mM) and TNFα (10 ng/mL) for 24 h. Blot Blot is representative representative of five independent experiments.
Densitometry analysis of LC3-II relative to β-actin is also shown, **P < 0.01, *P < 0.05. b Statistical analysis of apoptosis of PBMCs isolated from
patients with RA after treatment with 3-MA and TNFα. Results are expressed as AV-positive cells. Representative dot plots (PI on y-axis vs. AV
on x-axis) are also shown, **P < 0.01
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stimulate autophagy (TNFα and nutrient deprivation),
caused a significant reduction in LC3-II levels in cells
from patients with RA.
Consistent with previous literature data [14], differ-
ences in ability of etanercept to induce apoptosis be-
tween synoviocytes and peripheral cells were found also
in this study. While in FLS apoptosis was increased after
treatment with etanercept; in PBMCs from patients with
RA, a significant variation in apoptosis was found only
in the presence of TNFα and nutrient deprivation.
Since citrullination may be considered an additional
marker of autophagy in RA [33, 34], we analyzed the
levels of citrullinated proteins in PBMCs from pa-
tients with RA after incubation with etanercept. Ac-
cording to our previous paper [9], stimuli that induce
autophagy caused also an increase of citrullination.
Furthermore, etanercept reduced levels of citrullinated
proteins, confirming the inhibitory effect of etanercept
on autophagy.
Conclusions
To our knowledge, this is the first demonstration of a
direct involvement of the interplay between autophagy
and apoptosis in the response to therapy in patients
with RA. Although functions of autophagy appear to
be tissue and time specific, taken together, our data
show how autophagy activation can sustain survival of
immune cells from RA patients, influencing the ef-
fectiveness of the therapy. In fact, the restoration of
apoptosis mediated by suppression of TNF-mediated
Fig. 5 Evaluation of autophagy, apoptosis, and citrullination after in vitro treatment with etanercept in PBMCs from patients with RA. a LC3-II
levels in PBMCs purified from patients with RA after in vitro treatment with etanercept at concentration of 15 μg/ml. Where indicated, cells were
starved (1% FBS) or incubated with TNFα for 4 h, and then etanercept was added to the culture for 24 h. Densitometry analysis obtained in five
independent experiments is also shown, **P < 0.01, *P < 0.05. b Flow cytometry analysis of apoptosis after in vitro treatment with etanercept as
previously described. Results, referred to five independent experiments in PBMCs isolated from patients with RA, are expressed as percentage of
AV-positive apoptotic cells. Representative dot plots are shown (PI on y-axis vs. AV on x-axis), **P < 0.01. c Levels of citrullinated proteins in PBMCs
isolated from patients with RA treated with etanercept in vitro. Densitometric analysis is also shown. Data are obtained from five independent
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autophagy may be another mechanism of action to
explain the therapeutic effect of etanercept. Further
studies in a large cohort of patients are needed to
clarify whether a clinical approach based on autoph-
agy inhibition may be beneficial in RA.
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Additional file 1: Figure S1. Autophagy and apoptosis levels in PBMCs
isolated from responding (A) and non-responding (B) patients to anti-TNF
drugs alone or anti-TNF drugs plus methotrexate. Figure S2. Relation
between autophagy and citrullination in RA patients. A. Levels of anti-
cyclic citrullinated peptide antibodies (anti-CCP Abs) in patients with RA
before and after treatment with anti-TNF drugs. Values are expressed as
means ± sd. B. Correlation between anti-CCP antibodies levels (U/ml) and
spontaneous autophagy (expressed as LC3-II) and apoptosis (expressed as
percentage of Annexin V-positive cells). C. Changes in autophagy and
apoptosis before and after treatment with anti-TNF drugs in relation to
anti-CCP in RA responding patients. Figure S3. Flow cytometry gate
strategy for purification of CD4+, CD8+ T lymphocytes and B lympho-
cytes from patients with RA. Allophycocyanin = APC; Peridinin chlorophyll
protein = PerCP; Phycoerythrin = PE; Fluorescein isothiocyanate = FITC.
Figure S4. Effect of TNFα on apoptosis. Flow cytometry analysis of
apoptosis in PBMCs after treatment with TNFα. Apoptosis is expressed as
percentage of AV-positive cells. Representative dot plots (PI on y axis vs.
AV on x axis), chosen as representative of five experiments, are also
shown. Table S1. Clinical, demographic and serological characteristics of
patients with RA enrolled for sorting experiments (n = 8). (PDF 673 kb)
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